BRPI0514380A - amidas de ácido 5- e 6-amnoalquil indol-2-carboxìlico 3-substituìdo e análogos relacionados como inibidores de caseìna quinase i - Google Patents

amidas de ácido 5- e 6-amnoalquil indol-2-carboxìlico 3-substituìdo e análogos relacionados como inibidores de caseìna quinase i

Info

Publication number
BRPI0514380A
BRPI0514380A BRPI0514380-2A BRPI0514380A BRPI0514380A BR PI0514380 A BRPI0514380 A BR PI0514380A BR PI0514380 A BRPI0514380 A BR PI0514380A BR PI0514380 A BRPI0514380 A BR PI0514380A
Authority
BR
Brazil
Prior art keywords
formula
kinase inhibitors
amnoalkyl
carboxylic acid
acid amides
Prior art date
Application number
BRPI0514380-2A
Other languages
English (en)
Inventor
William Arthur Metz
Fa-Xiang Ding
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of BRPI0514380A publication Critical patent/BRPI0514380A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

AMIDAS DE áCIDO 5-E 6-AMNOALQUIL INDOL-2-CARBOXìLICO 3-SUBSTITUìDO E ANáLOGOS RELACIONADOS COMO INIBIDORES DE CASEìNA QUINASE A presente invenção refere-se e reivindica compostos de fórmula (1) e fórmula (II) como inibidores da caseína quinase Ie humana, e métodos de uso dos ditos compostos de fórmula (1) e fórmula (II) para o tratamento de doenças e transtornos do sistema nervoso central, incluindo transtornos do humor e transtornos do sono. Também se apresentam e reivindicam composições farmacêuticas compreendendo compostos de fórmula (I) ou fórmula (II).
BRPI0514380-2A 2004-08-19 2005-08-16 amidas de ácido 5- e 6-amnoalquil indol-2-carboxìlico 3-substituìdo e análogos relacionados como inibidores de caseìna quinase i BRPI0514380A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60338004P 2004-08-19 2004-08-19
PCT/US2005/029053 WO2006023467A1 (en) 2004-08-19 2005-08-16 3-SUBSTITUTED-5- AND 6-AMINOALKYL INDOLE-2-CARBOXYLIC ACID AMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE Iϵ

Publications (1)

Publication Number Publication Date
BRPI0514380A true BRPI0514380A (pt) 2008-06-10

Family

ID=35311279

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0514380-2A BRPI0514380A (pt) 2004-08-19 2005-08-16 amidas de ácido 5- e 6-amnoalquil indol-2-carboxìlico 3-substituìdo e análogos relacionados como inibidores de caseìna quinase i

Country Status (26)

Country Link
US (2) US7629376B2 (pt)
EP (1) EP1794122B1 (pt)
JP (1) JP4843608B2 (pt)
KR (2) KR20130038409A (pt)
CN (1) CN101006055B (pt)
AR (1) AR050919A1 (pt)
AT (1) ATE508112T1 (pt)
AU (1) AU2005277523B2 (pt)
BR (1) BRPI0514380A (pt)
CA (1) CA2577667C (pt)
DE (1) DE602005027858D1 (pt)
GT (1) GT200500214A (pt)
IL (1) IL181156A (pt)
JO (1) JO2724B1 (pt)
MA (1) MA28863B1 (pt)
MX (1) MX2007001382A (pt)
NO (1) NO20071466L (pt)
NZ (1) NZ552800A (pt)
PA (1) PA8642901A1 (pt)
PE (1) PE20060498A1 (pt)
RU (1) RU2369599C2 (pt)
SV (1) SV2006002192A (pt)
TW (1) TWI357897B (pt)
UY (1) UY29078A1 (pt)
WO (1) WO2006023467A1 (pt)
ZA (1) ZA200700651B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2397481B1 (en) * 2009-02-12 2014-03-12 Pharmadesign, Inc. Inhibitor of casein kinase 1delta and casein kinase 1epsilon
KR20120044281A (ko) * 2009-04-17 2012-05-07 사일린 파마슈티칼스, 인크 단백질 키나제 ｃｋ2 활성과 관련된 장애의 치료 방법
BR112014032581A8 (pt) 2012-06-27 2018-08-14 4Sc Discovery Gmbh inibidores de bifluorodioxalano-amino-benzimidazol quinase para o tratamento de câncer, distúrbios do snc e inflamação autoimune
JP2021511364A (ja) 2018-01-29 2021-05-06 カディラ ヘルスケア リミティド 抗菌剤として有用な複素環式化合物
WO2022006377A2 (en) * 2020-07-02 2022-01-06 Mbq Pharma Heterocyclic inhibitors of rho gtpases for the treatment of disease
US12209078B2 (en) 2021-10-06 2025-01-28 Mbq Pharma Crystalline forms of carbazole inhibitors of RhoGTPase for the treatment of disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5296471A (en) 1992-12-22 1994-03-22 Glycomed Incorporated Method for controlling o-desulfation of heparin and compositions produced thereby
KR100722176B1 (ko) * 1999-06-08 2007-05-29 아벤티스 파마슈티칼스 인크. 일주기 리듬 단백질을 변화시키기 위한 스크리닝 방법
RU2269523C2 (ru) * 2000-04-28 2006-02-10 Акадиа Фармасьютикалз, Инк. Мускариновые агонисты
WO2004014851A2 (en) * 2002-08-09 2004-02-19 Merck & Co., Inc. Tyrosine kinase inhibitors
DE602004020685D1 (de) * 2003-12-11 2009-05-28 Aventis Pharma Inc Substituierte 1h-pyrroloä3,2-b, 3,2-c und 2,3-cüpyridin-2-carbonsäureamide und verwandte analoga als inhibitoren von caseinkinase-i-epsilon

Also Published As

Publication number Publication date
RU2369599C2 (ru) 2009-10-10
TW200621711A (en) 2006-07-01
MA28863B1 (fr) 2007-09-03
GT200500214A (es) 2006-03-27
IL181156A0 (en) 2007-07-04
JP2008510017A (ja) 2008-04-03
NZ552800A (en) 2010-11-26
CA2577667C (en) 2011-01-04
RU2007109783A (ru) 2008-09-27
NO20071466L (no) 2007-04-19
MX2007001382A (es) 2007-04-19
CA2577667A1 (en) 2006-03-02
UY29078A1 (es) 2006-03-31
AR050919A1 (es) 2006-12-06
ATE508112T1 (de) 2011-05-15
EP1794122A1 (en) 2007-06-13
EP1794122B1 (en) 2011-05-04
US20090082340A1 (en) 2009-03-26
DE602005027858D1 (de) 2011-06-16
TWI357897B (en) 2012-02-11
US20080027124A1 (en) 2008-01-31
ZA200700651B (en) 2008-09-25
IL181156A (en) 2011-09-27
SV2006002192A (es) 2006-06-28
WO2006023467A1 (en) 2006-03-02
PE20060498A1 (es) 2006-07-10
PA8642901A1 (es) 2006-05-16
AU2005277523B2 (en) 2011-09-29
KR20130038409A (ko) 2013-04-17
JO2724B1 (en) 2013-09-15
JP4843608B2 (ja) 2011-12-21
CN101006055B (zh) 2011-06-22
CN101006055A (zh) 2007-07-25
KR20070043012A (ko) 2007-04-24
AU2005277523A1 (en) 2006-03-02
HK1105196A1 (en) 2008-02-06
US7923466B2 (en) 2011-04-12
US7629376B2 (en) 2009-12-08

Similar Documents

Publication Publication Date Title
BRPI0417520A (pt) 1h-pirrolo[3,2-b, 3,2-c, e 2,3-c]piridina-2-carboxamidas substituìdas e análogos relatados como inibidores de caseìna cinase i-epsilon
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
BR0312729A (pt) Novos derivados de indol-3-enxofre
BRPI0408369A (pt) derivados de indol úteis para o tratamento de doenças
MA33119B1 (fr) Derives de benzofuranyle utilises comme inhibiteurs de la glucokinase
EA200602191A1 (ru) 5,5-дизамещённые-2-амино-4-тиазолидиноны и способ их получения, фармацевтическая композиция и способ лечения
BR0309664A (pt) Derivados de [1,4]diazepino[6,7,1-ij]quinolina como agentes anti-psicóticos e antiobesidade
BRPI0418099A (pt) compostos, composição farmacêutica, e uso de um composto
BRPI0515991A (pt) derivados de bisariluréia substituìda heterocìclica como inibidores de cinase
JO2629B1 (en) Branched carboxylic acid amides containing thienobirol, carboxylic acid amides containing pyrolithiazole, and the like as kinase inhibitors casein epsilon
NO20071466L (no) 3-substituerte-5- og 6-aminoalkyl indol-2-karboksylsyreamider og relaterte analoger som inhibitorer av kaseinkinase IE
WO2005062992A3 (en) Substituted melatonin derivatives, process for their preparation, and methods of use
BRPI0809873A2 (pt) "composto, processo para a preparação do composto, método para o tratamento de uma desordem do sistema nervoso central, composição farmacêutica, uso do composto, método para testar antagonistas e antagonistas com seletividade para o receptor 5-th6 e método de tratamento"
BR0308515A (pt) Combinação de um antagonista de receptor de aldosterona com ácido nicotìnico ou um derivado de ácido nicotìnico
ATE407120T1 (de) 3-((hetero)arylsulfonyl)-8- ä(aminoalkyl)oxyüchinoline als antagonisten des 5-ht6-rezeptors zur behandlung von erkrankungen des zns
ATE444069T1 (de) Chinolin-derivate zur behandlung von mglur5- rezeptor-vermittelten erkrankungen
TW200519102A (en) Hydronopol substituted benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors
IS8096A (is) Notkun karbamasepínafleiða til að meðhöndla órósemi í sjúklingum er þjást af vitglöpum
NO20065551L (no) Anvendelse av opoid reseptor antagonistforbindelser for forhindring og/eller behandling av sykdommer assosiert med malet calcineurin
BRPI0409505A (pt) compostos como antagonistas do receptor crf1
WO2009064836A3 (en) Kynurenine-aminotransferase inhibitors
UA86873C2 (en) SUBSTITUTED ARYL 1,4-PYRAZlNE DERIVATIVES
DE602004019129D1 (de) Verwendung von 1-oxadibenzo äe,hü azulenen zur herstellung von pharmazeutischen formulierungen für die behandlung und prävention von erkrankungen und
BR0308494A (pt) Combinação de um antagonista de receptores de aldosterona e de um derivado do ácido fìbrico
DE602006018149D1 (de) Substituierte triazolderivate und ihre verwendung als antagonisten des neurokinin-3-rezeptors

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: AVENTIS PHARMACEUTICALS, INC. (US)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020070165509/RJ DE 23/11/2007.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2320 DE 23-06-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.